2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Jean-Marie Michot, MD, discusses the examination of CC-99282 in relapsed/refractory non–Hodgkin lymphoma.
Jean-Marie Michot, MD, medical oncologist, the Department of Hematology and Innovative Drugs, the Institut de Cancérologie Gustave Roussy, discusses the examination of CC-99282 in relapsed/refractory non–Hodgkin lymphoma (NHL).
Because there are few options for treatment in patients with relapsed/refractory NHL, investigations are ongoing to find new chemotherapy-free therapy options, Michot says. This has led to the examination of CC-99282 as a chemotherapy-free treatment, and the agent is based on protein degraders acting as molecular glue degraders, Michot explains.
Preclinical models demonstrated that when compared with other immunomodulatory agents, CC-99282 produced an increased apoptotic and antiproliferative activity, Michot adds. These data led to the rationale of utilizing this agent in a phase 1 trial (NCT03930953), where findings from the dose escalation portion of the trial showed that CC-99282 demonstrated encouraging responses and a favorable safety profile, with low rates of serious febrile neutropenia, Michot concludes.